Product Details
| Product Name:
VU0359595 |
CAS No.:
1246303-14-9 |
| Purity:
99.15% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | VU0359595 |
| Description | VU0359595 (ML-270) is a potent and selective pharmacological phospholipase D1 (PLD1) inhibitor with an IC50 of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC50 of 6.4 μM). VU0359595 can be used for the research of cancer, diabetes, neurodegenerative and inflammatory diseases. |
| In vitro | VU0359595, at concentrations ranging from 5 to 5000 nM, inhibits both the baseline and FCS/IGF-1 stimulated proliferation of astroglial cells. At doses of 5, 50, and 500 nM, with a 30-min exposure, it does not impact the basal phospholipase D (PLD) activity in astrocytes; however, it significantly reduces mitogen-stimulated PLD activity in a concentration-dependent manner[2]. Additionally, at a concentration of 0.15 μM administered 1 h before and during a 4 h high glucose treatment, VU0359595 notably decreases the high glucose-induced increase in [3H]-phosphatidylethanol (PEth) generation in retinal pigment epithelium (RPE) cells[3]. When applied at 5 μM one hour before lipopolysaccharide (LPS) treatment, it modulates autophagy in LPS-induced RPE cells undergoing a 24-h treatment with 10 μg/ml of LPS[4]. Furthermore, a 2 nM pre-exposure for 30 min effectively blocks the gliotoxin (50 ng/ml)-enhanced internalization of A. fumigatus in A549 cells[5]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 4.98 mg/mL (10 mM), Sonication is recommended.
|
| Keywords | VU0359595 | ML270 | ML 270 | VU-0359595 | CID 53361951 | CID53361951 | VU 0359595 |
| Inhibitors Related | Neomycin sulfate | 1-Naphthaleneacetic acid potassium salt | trans-Benzylideneacetone | Benzylideneacetone | Tris(2,4-di-tert-butylphenyl)phosphate | (E/Z)-Polydatin | Indomethacin | Fluticasone (propionate) | 1-Naphthaleneacetic acid | Darapladib | Lansoprazole | Amentoflavone |
| Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1370554-01-0
$58.00 / 1mg
-
CAS:2143475-98-1
$35.00 / 5mg
-
CAS:523-92-2
$43.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States